Suzanne Topalian
MD
Associate Director, Bloomberg-Kimmel Institute for Cancer Immunotherapy
👥Biography 个人简介
Suzanne Topalian led the first clinical trials of anti-PD-1 therapy (nivolumab) demonstrating durable responses across multiple cancer types, launching a therapeutic revolution. Her subsequent work on PD-L1 as a predictive biomarker has guided immunotherapy patient selection. She is one of the most important translational scientists in the history of cancer immunotherapy.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 Suzanne Topalian 的研究动态
Follow Suzanne Topalian's research updates
留下邮箱，当我们发布与 Suzanne Topalian（Johns Hopkins University）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment